In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axerion Therapeutics Inc.

www.axeriontherapeutics.com

Latest From Axerion Therapeutics Inc.

AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013

Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.

BioPharmaceutical Deals

AstraZeneca Teams With Vanderbilt In Neuroscience Pact

Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.

Biopharma Quarterly Deal Statistics, Q2 2012

Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.

BioPharmaceutical Deals

Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain

AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Axerion Therapeutics Inc.
  • Senior Management
  • Synvia McBrinn, Pres. & CEO
    Sean Cassidy , VP, Fin. & Admin. & CFO
    George D Maynard, PhD, VP, Preclinical Dev.
  • Contact Info
  • Axerion Therapeutics Inc.
    Phone: (203) 492-0550
    555 Long Wharf Dr., 11th Fl.
    New Haven, CT 06511
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register